Developer docs
API playgroundTry for free, no card

Search company profiles

EuroLyser

Full company profile

uuid000kmo8

Namestring
EuroLyser
Legal namestring
EUROLyser Diagnostica GmbH
Websiteurl
eurolyser.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

EUROLyser Diagnostica GmbH (EuroLyser), headquartered in Salzburg, Austria, and operating as an affiliate of Mars, Incorporated, develops and manufactures point-of-care diagnostic instruments and single-use test kits for two segments: human medical diagnostics and veterinary diagnostics. The core instrument line consists of the CUBE and CUBE-S analyzers (for human use) and the CUBE-VET and EUROLyser solo analyzers (for veterinary use), all built around a factory-calibrated, maintenance-free architecture with an Android-based tablet interface, RFID-enabled reagent kits that carry pre-set calibration curves and lot/expiry data, and bidirectional ASTM/HL7 connectivity to practice management software, HIS, and LIMS systems. The underlying assay technology relies on homogeneous immunoturbidimetric and enzymatic measurement methods, with a reagent menu covering inflammation (CRP, hsCRP, SAA, cCRP, Fibrinogen), kidney function (Cystatin C, SDMA, NH3), metabolic and endocrine markers (HbA1c, BHB, Fructosamine, Cortisol, T4), liver function (GLDH), cardiac markers (Troponin I), coagulation (D-Dimer), anemia (Ferritin), reproductive health (canine, bovine and equine Progesterone), drug monitoring (Phenobarbital), and screening (iFOB, Lipoprotein(a)), with most tests delivering results in under ten minutes.

The company monetizes through a razor-and-blade model: upfront sales of instruments followed by recurring revenue from proprietary single-use test kits, which are sold in 6- and 16-test pack sizes alongside control kits. Go-to-market is primarily indirect, executed through a network of authorized distributors covering more than 30 countries across Europe (Germany, Denmark, Italy, Netherlands, Poland, Romania, Switzerland, Austria and others), Asia (Japan via Sysmex, South Korea, Taiwan), the Middle East (Israel, Iraq), Africa (Morocco, Tanzania), and the Americas (USA, Canada, Caribbean). EUROLyser supplements this with a direct sales portal for the Austrian market, an eHealth/telemedicine-optimized CUBE-S variant, and software tools including ConneXport for PC data transfer and the EVOS cloud platform for veterinary data synchronization. The company holds ISO 13485:2016 and ISO 27001:2022 certifications, which underpin its ability to sell CE-marked in-vitro diagnostic devices into regulated healthcare markets, and it serves primary customer segments of physician practices and hospital ERs (human diagnostics) and companion-animal and production-animal veterinary clinics (veterinary diagnostics).

Short descriptiontext

EUROLyser Diagnostica GmbH develops point-of-care diagnostic instruments (CUBE, CUBE-S, CUBE-VET) and single-use immunoturbidimetric and enzymatic test kits, serving physician practices, hospital ERs, and veterinary clinics across more than 30 countries through a global distributor network as an affiliate of Mars, Incorporated.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSalzburg, Austria
HQ citystring
Salzburg
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, veterinary diagnostic instruments, medical diagnostic analyzers, immunoturbidimetric test kits, clinical chemistry analyzers
Industry2 codes
1Laboratory & Point-of-Care Diagnostic Devices (Analyzers, Test Kits, Microscopy)
CodeHLAMAFAIPrimaryYes
2Point-of-Care & In-Clinic Diagnostics (Rapid Tests, Benchtop Analyzers)
CodeHLAMADAIPrimaryNo
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
Product category
Point-of-Care Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Point-of-care diagnostic instruments
TypeHardware Sales
Description

Sale of CUBE, CUBE-S, and CUBE-VET instruments along with solo veterinary analyzer for point-of-care testing in medical practices and veterinary clinics.

eurolyser.com
2Single-use test kits and reagents
TypeHardware Sales
Description

Recurring revenue from sale of test kits (CRP, Cystatin C, SDMA, cortisol, etc.) that are consumed with each test. Test kits come in various pack sizes (6 or 16 tests) and include control kits.

eurolyser.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1CUBE
Description

Point-of-care medical diagnostic instrument series with Android-based interface and tablet PC for human diagnostics.

eurolyser.com
+5 more records
Core offering1 text field

EuroLyser Diagnostica GmbH designs, manufactures, and distributes point-of-care diagnostic instruments and single-use test kits for both human medical diagnostics and veterinary diagnostics. The product portfolio centers on the CUBE-series analyzers (CUBE-S for human use, CUBE-VET for veterinary use) with Android-based tablet interfaces, the EUROLyser solo veterinary analyzer, and the EUROLyser smart medical analyzer, paired with a broad menu of immunoturbidimetric and enzymatic reagent kits covering inflammation, kidney function, cardiac markers, diabetes, reproductive health, and metabolic monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Test results available in minutes rather than days
+1 more record
Product overview1 text field

EUROLyser Diagnostica GmbH is a point-of-care diagnostics company offering a portfolio of instruments and single-use test kits for both medical (human) and veterinary diagnostics. The core product lines include the CUBE-S and CUBE-VET analyzers (with Android-based tablet interfaces), the EUROLyser solo (veterinary predecessor), and the EUROLyser smart (medical). The company provides an extensive menu of compatible test reagents covering inflammation (CRP, SAA, Fibrinogen), metabolic disorders (Cortisol, T4, Fructosamine, Lactate), kidney function (SDMA, Cystatin C, NH3), liver function (GLDH), cardiac markers (Troponin I), diabetes (HbA1c, BHB), reproduction (Progesterone variants), coagulation (D-Dimer), and drug monitoring (Phenobarbital). Software tools include ConneXport for PC data transfer and EVOS for cloud-based result accessibility. All products are designed for point-of-care use with rapid turnaround times (typically under 10 minutes) and maintenance-free operation.

Product and service1 record
1CUBE-S
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-02-07
Description

Sysmex Corporation, a global market leader in hematology, and EUROLyser Diagnostica expanded their successful cooperation to include sales of EUROLyser's point-of-care systems measuring CRP (C-reactive protein) in the Japanese market. The Japanese market is globally acknowledged as 'high end' in terms of laboratory systems. Sysmex is responsible for distributing EUROLyser products in Japan, leveraging their established presence and reputation in the Japanese healthcare market.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IDEXX is the global leader in companion-animal diagnostics (Catalyst, ProCyte, SediVue) and competes head-to-head with EUROLyser's veterinary menu across in-clinic analyzers and consumables.

TypeBroad incumbent
Description

Abbott's i-STAT is the dominant handheld point-of-care analyzer for human diagnostics (chemistry, cardiac, coagulation). EUROLyser competes in the same POC analyzers + single-use-cartridge model for physicians and ERs.

TypeEmerging player
Description

Swiss specialty diagnostics company with a strong fecal/calprotectin and veterinary assay menu. Comparable as a focused specialty-IVD reagent maker overlapping with EUROLyser on select veterinary and inflammatory tests.

TypeDirect peer
Description

EKF builds point-of-care analyzers and reagents (QuikRead, Hemo Control) for clinical and veterinary markets, with a similar razor/blade consumable model and customer base to EUROLyser.

TypeBroad incumbent
Description

Roche's cobas Liat and broader POC portfolio compete in physician-office and hospital rapid testing — same clinical use cases (CRP, HbA1c, D-Dimer) as EUROLyser CUBE/CUBE-S.

TypeDirect peer
Description

Nova manufactures StatStrip and other POC blood-gas/chemistry analyzers and consumables; competes with EUROLyser in physician-office and hospital POC chemistry segments.

TypeBroad incumbent
Description

QuidelOrtho's Triage and Sofia platforms serve rapid POC immunoassay testing in clinics and hospitals — broadly overlapping EUROLyser's cardiology/inflammation tests (Troponin, CRP, D-Dimer).

TypeDirect peer
Description

Zoetis's Vetscan line is a direct competitor to CUBE-VET and EUROLyser solo in veterinary point-of-care diagnostics (chemistry, hematology, immunoassays), sold through veterinary channels globally.

TypeDirect peer
Description

Heska, now part of Mars-owned Antech, sells in-clinic veterinary analyzers and consumables. Direct competitor to CUBE-VET, and notably a Mars sister company — making it both ally and rival.

TypeEmerging player
Description

Trinity Biotech develops POC clinical chemistry and immunology tests (e.g., HIV, hemoglobin A1c) sold via distributor networks globally — same razor/blade consumable model and customer profile as EUROLyser.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EuroLyser

Point-of-Care Diagnosticseurolyser.com

EUROLyser Diagnostica GmbH develops point-of-care diagnostic instruments (CUBE, CUBE-S, CUBE-VET) and single-use immunoturbidimetric and enzymatic test kits, serving physician practices, hospital ERs, and veterinary clinics across more than 30 countries through a global distributor network as an affiliate of Mars, Incorporated.

What EuroLyser does

EUROLyser Diagnostica GmbH (EuroLyser), headquartered in Salzburg, Austria, and operating as an affiliate of Mars, Incorporated, develops and manufactures point-of-care diagnostic instruments and single-use test kits for two segments: human medical diagnostics and veterinary diagnostics. The core instrument line consists of the CUBE and CUBE-S analyzers (for human use) and the CUBE-VET and EUROLyser solo analyzers (for veterinary use), all built around a factory-calibrated, maintenance-free architecture with an Android-based tablet interface, RFID-enabled reagent kits that carry pre-set calibration curves and lot/expiry data, and bidirectional ASTM/HL7 connectivity to practice management software, HIS, and LIMS systems. The underlying assay technology relies on homogeneous immunoturbidimetric and enzymatic measurement methods, with a reagent menu covering inflammation (CRP, hsCRP, SAA, cCRP, Fibrinogen), kidney function (Cystatin C, SDMA, NH3), metabolic and endocrine markers (HbA1c, BHB, Fructosamine, Cortisol, T4), liver function (GLDH), cardiac markers (Troponin I), coagulation (D-Dimer), anemia (Ferritin), reproductive health (canine, bovine and equine Progesterone), drug monitoring (Phenobarbital), and screening (iFOB, Lipoprotein(a)), with most tests delivering results in under ten minutes.

The company monetizes through a razor-and-blade model: upfront sales of instruments followed by recurring revenue from proprietary single-use test kits, which are sold in 6- and 16-test pack sizes alongside control kits. Go-to-market is primarily indirect, executed through a network of authorized distributors covering more than 30 countries across Europe (Germany, Denmark, Italy, Netherlands, Poland, Romania, Switzerland, Austria and others), Asia (Japan via Sysmex, South Korea, Taiwan), the Middle East (Israel, Iraq), Africa (Morocco, Tanzania), and the Americas (USA, Canada, Caribbean). EUROLyser supplements this with a direct sales portal for the Austrian market, an eHealth/telemedicine-optimized CUBE-S variant, and software tools including ConneXport for PC data transfer and the EVOS cloud platform for veterinary data synchronization. The company holds ISO 13485:2016 and ISO 27001:2022 certifications, which underpin its ability to sell CE-marked in-vitro diagnostic devices into regulated healthcare markets, and it serves primary customer segments of physician practices and hospital ERs (human diagnostics) and companion-animal and production-animal veterinary clinics (veterinary diagnostics).

EuroLyser firmographics

Firmographics
Name
EuroLyser
Legal name
EUROLyser Diagnostica GmbH
Website
https://eurolyser.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
1–10 employees
Short description
EUROLyser Diagnostica GmbH develops point-of-care diagnostic instruments (CUBE, CUBE-S, CUBE-VET) and single-use immunoturbidimetric and enzymatic test kits, serving physician practices, hospital ERs, and veterinary clinics across more than 30 countries through a global distributor network as an affiliate of Mars, Incorporated.
Ownership category
akta.pro rank

EuroLyser industry classification

Industry
Product category
Point-of-Care Diagnostics
NAICS
Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Laboratory & Point-of-Care Diagnostic Devices (Analyzers, Test Kits, Microscopy) (HLAMAFAI)
akta.pro secondary industry
Point-of-Care & In-Clinic Diagnostics (Rapid Tests, Benchtop Analyzers) (HLAMADAI)

Keywords

  • Point-of-care diagnostics
  • Veterinary diagnostic instruments
  • Medical diagnostic analyzers
  • Immunoturbidimetric test kits
  • Clinical chemistry analyzers

Where EuroLyser is headquartered

Location

Headquarters

HQ city
Salzburg
HQ country
Austria
HQ region
Europe

Offices1 record

Markets served

EuroLyser business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Point-of-care diagnostic instruments: Sale of CUBE, CUBE-S, and CUBE-VET instruments along with solo veterinary analyzer for point-of-care testing in medical practices and veterinary clinics.
  2. Single-use test kits and reagents: Recurring revenue from sale of test kits (CRP, Cystatin C, SDMA, cortisol, etc.) that are consumed with each test. Test kits come in various pack sizes (6 or 16 tests) and include control kits.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

EuroLyser product offering

Product offering

Core offering

EuroLyser Diagnostica GmbH designs, manufactures, and distributes point-of-care diagnostic instruments and single-use test kits for both human medical diagnostics and veterinary diagnostics. The product portfolio centers on the CUBE-series analyzers (CUBE-S for human use, CUBE-VET for veterinary use) with Android-based tablet interfaces, the EUROLyser solo veterinary analyzer, and the EUROLyser smart medical analyzer, paired with a broad menu of immunoturbidimetric and enzymatic reagent kits covering inflammation, kidney function, cardiac markers, diabetes, reproductive health, and metabolic monitoring.

Product overview

EUROLyser Diagnostica GmbH is a point-of-care diagnostics company offering a portfolio of instruments and single-use test kits for both medical (human) and veterinary diagnostics. The core product lines include the CUBE-S and CUBE-VET analyzers (with Android-based tablet interfaces), the EUROLyser solo (veterinary predecessor), and the EUROLyser smart (medical). The company provides an extensive menu of compatible test reagents covering inflammation (CRP, SAA, Fibrinogen), metabolic disorders (Cortisol, T4, Fructosamine, Lactate), kidney function (SDMA, Cystatin C, NH3), liver function (GLDH), cardiac markers (Troponin I), diabetes (HbA1c, BHB), reproduction (Progesterone variants), coagulation (D-Dimer), and drug monitoring (Phenobarbital). Software tools include ConneXport for PC data transfer and EVOS for cloud-based result accessibility. All products are designed for point-of-care use with rapid turnaround times (typically under 10 minutes) and maintenance-free operation.

Differentiator

Problem solved

Functional benefit

Brands

  • CUBE: Point-of-care medical diagnostic instrument series with Android-based interface and tablet PC for human diagnostics.
  • CUBE-S
  • CUBE-VET
  • EUROLyser solo
  • ConneXport
  • EVOS

Products and services

  • CUBE-S

Quantifiable outcome

  • Test results available in minutes rather than days
  • +1 more outcomes

Companies that use EuroLyser

Customer profile

Segments2 records

Ideal customer profiles2 records

EuroLyser technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

Feature5 records

EuroLyser partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Sysmex CorporationcoreChannel Partner/ Reseller/ Distributor · 7 February 2019Sysmex Corporation, a global market leader in hematology, and EUROLyser Diagnostica expanded their successful cooperation to include sales of EUROLyser's point-of-care systems measuring CRP (C-reactive protein) in the Japanese market. The Japanese market is globally acknowledged as 'high end' in terms of laboratory systems. Sysmex is responsible for distributing EUROLyser products in Japan, leveraging their established presence and reputation in the Japanese healthcare market.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

EuroLyser competitors and assessment

Company assessment

Broad incumbents

  • IDEXX Laboratories: IDEXX is the global leader in companion-animal diagnostics (Catalyst, ProCyte, SediVue) and competes head-to-head with EUROLyser's veterinary menu across in-clinic analyzers and consumables.
  • Abbott (i-STAT): Abbott's i-STAT is the dominant handheld point-of-care analyzer for human diagnostics (chemistry, cardiac, coagulation). EUROLyser competes in the same POC analyzers + single-use-cartridge model for physicians and ERs.
  • Roche Diagnostics (cobas): Roche's cobas Liat and broader POC portfolio compete in physician-office and hospital rapid testing — same clinical use cases (CRP, HbA1c, D-Dimer) as EUROLyser CUBE/CUBE-S.
  • QuidelOrtho: QuidelOrtho's Triage and Sofia platforms serve rapid POC immunoassay testing in clinics and hospitals — broadly overlapping EUROLyser's cardiology/inflammation tests (Troponin, CRP, D-Dimer).

Emerging players

  • Bühlmann Laboratories: Swiss specialty diagnostics company with a strong fecal/calprotectin and veterinary assay menu. Comparable as a focused specialty-IVD reagent maker overlapping with EUROLyser on select veterinary and inflammatory tests.
  • Trinity Biotech: Trinity Biotech develops POC clinical chemistry and immunology tests (e.g., HIV, hemoglobin A1c) sold via distributor networks globally — same razor/blade consumable model and customer profile as EUROLyser.

Direct peers

  • EKF Diagnostics: EKF builds point-of-care analyzers and reagents (QuikRead, Hemo Control) for clinical and veterinary markets, with a similar razor/blade consumable model and customer base to EUROLyser.
  • Nova Biomedical: Nova manufactures StatStrip and other POC blood-gas/chemistry analyzers and consumables; competes with EUROLyser in physician-office and hospital POC chemistry segments.
  • Zoetis (Vetscan): Zoetis's Vetscan line is a direct competitor to CUBE-VET and EUROLyser solo in veterinary point-of-care diagnostics (chemistry, hematology, immunoassays), sold through veterinary channels globally.
  • Heska (acquired by Mars/Antech): Heska, now part of Mars-owned Antech, sells in-clinic veterinary analyzers and consumables. Direct competitor to CUBE-VET, and notably a Mars sister company — making it both ally and rival.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

EuroLyser social profiles

Digital presence

EuroLyser compliance and trust

Trust signal

Compliance2 records

EuroLyser financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EuroLyser leadership team

Management profile

Number of profiles

Profiles3 records

EuroLyser funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EuroLyser M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EuroLyser

What does EuroLyser do?

EuroLyser Diagnostica GmbH designs, manufactures, and distributes point-of-care diagnostic instruments and single-use test kits for both human medical diagnostics and veterinary diagnostics. The product portfolio centers on the CUBE-series analyzers (CUBE-S for human use, CUBE-VET for veterinary use) with Android-based tablet interfaces, the EUROLyser solo veterinary analyzer, and the EUROLyser smart medical analyzer, paired with a broad menu of immunoturbidimetric and enzymatic reagent kits covering inflammation, kidney function, cardiac markers, diabetes, reproductive health, and metabolic monitoring.

Is EuroLyser a public or private company?

EuroLyser is a private company. It is classified as corporate owned and is currently operating.

When was EuroLyser founded?

EuroLyser was founded in 2003. It employs 1 to 10 people.

Where is EuroLyser based?

EuroLyser is headquartered in Salzburg, Austria, in the Europe region.

How does EuroLyser make money?

Two revenue lines are on record. Point-of-care diagnostic instruments are the primary driver. The others are single-use test kits and reagents.

Who are EuroLyser's main competitors?

Broad incumbents on record are IDEXX Laboratories, Abbott (i-STAT), Roche Diagnostics (cobas) and QuidelOrtho. Emerging players are Bühlmann Laboratories and Trinity Biotech. Direct peers are EKF Diagnostics, Nova Biomedical, Zoetis (Vetscan) and Heska (acquired by Mars/Antech).

Does EuroLyser have an API?

No public API is recorded for EuroLyser.

What industry is EuroLyser in?

EuroLyser's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAMAFAI, Laboratory & Point-of-Care Diagnostic Devices (Analyzers, Test Kits, Microscopy), with a secondary code of HLAMADAI, Point-of-Care & In-Clinic Diagnostics (Rapid Tests, Benchtop Analyzers). Its NAICS code is 334516 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comUnited States Veterinary Point of Care Diagnostics Industry Forecast in 2025 | Point of Care Devices Transform Animal Treatment | Top Companies are Eurolyser Diagnostica GmbH, Woodley Equipment CompanDataM Intelligence released a market report on the veterinary point-of-care diagnostics industry, forecasting strong growth from 2025 to 2032. The report highlights key players such as Zoetis, IDEXX, and Heska, and notes recent developments including new rapid assays and telemedicine integrations. It also cites limited reimbursement and low pet insurance penetration as challenges.ArchimedARCHIMED’s MED II fund earns a 6x return on EUROLyser, its first exitARCHIMED sold point-of-care diagnostics specialist EUROLyser to Antech Diagnostics, marking its first exit and earning a 6x return on the investment. The transaction allows EUROLyser's technology to expand into Europe and beyond while returning more than half of MED II fund capital to investors. During its three-year holding period, ARCHIMED increased EUROLyser's profits by more than two-fold through strategic operational improvements.PR NewswireWorldwide Ferritin Testing Industry to 2027 - Government Initiatives to Reduce Anemia Burden Worldwide Presents OpportunitiesThe global ferritin testing market was valued at US$ 372.05 million in 2019 and is projected to reach US$ 556.19 million by 2027, growing at a CAGR of 5.3% from 2020 to 2027. Market growth is driven by the increasing burden of iron deficiency disorders and the aging population, though the availability of advanced technologies may restrain market expansion. The report identifies anemia as the largest market segment in 2019, with key players including Eurolyser Diagnostica GmbH, bioMerieux SA, and Thermo Fisher Scientific Inc. operating in this space.